Full text
Earnings transcript
Read the complete earnings call transcript.
EMBC
Embecta Corp.
$6.7
0.62
(10.12%)
| Exchange: | NASDAQ |
| Market Cap: | 379.336M |
| Shares Outstanding: | 58.309M |
Delayed data
About The Company
| Sector: | HealthcareView sector performance | |||||
| Industry: | Medical – Instruments & SuppliesView industry performance | |||||
| CEO: | Devdatt Kurdikar | |||||
| Full Time Employees: | 1850 | |||||
| Address: |
| |||||
| Website: | https://www.embecta.com |
Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in 1924, Embecta’s headquarters are located in Parsippany, New Jersey. The company transitioned to an independent entity from Becton, Dickinson and Company on April 1, 2022.
Click to read more…
Revenue Segmentation
Revenue by type
Revenue by region
EMBC full analysis
Welcome to MARKETSNAP’s SWOT analysis for Embecta Corp., also known by its ticker EMBC. If you’re a long-term investor looking to build wealth through smart stock picks, you’re in the right place. Today, we’re diving deep into Embecta Corp., a player in the healthcare sector, specifically within the medical devices industry. For those who might not be as familiar, Embecta focuses on diabetes care solutions, a critical and growing niche in healthcare. They’ve carved out a space in providing products…
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 1,120,800 | 1,123,100 | 1,080,400 |
| Gross Profit | 749,900 | 728,900 | 679,500 |
| EBITDA | 245,300 | 192,700 | 284,300 |
| Operating Income | 229,600 | 174,200 | 329,300 |
| Net Income | 70,400 | 78,300 | 95,400 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 1,214,400 | 1,285,300 | 1,090,900 |
| Total Liabilities | 2,036,100 | 2,023,600 | 1,741,500 |
| Total Stockholders Equity | -821,700 | -738,300 | -650,600 |
| Total Debt | 1,659,800 | 1,608,400 | 1,430,300 |
| Cash and Cash Equivalents | 326,500 | 267,500 | 225,500 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 67,700 | 35,700 | 191,700 |
| Capital Expenditure | -26,500 | -15,800 | -9,300 |
| Free Cash Flow | 41,200 | 19,900 | 182,400 |
| Net Income | 70,400 | 78,300 | 95,400 |
| Net Change in Cash | -4,400 | -52,300 | -45,600 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 1,091,929.017 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 1,095,782.954 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 1,094,000 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | 357,500.351 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | 358,513.027 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | 358,044.638 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | 179,836.273 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | 180,661.672 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | 180,279.903 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 306,526.701 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 307,608.580 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 307,108.068 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | 3.060 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | 3.070 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | 3.050 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 1 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 1 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Solid Revenue Performance: Embecta Corp. reported $261.9 million in revenue for the fiscal first quarter of 2025, as highlighted in the earnings call transcript. This demonstrates a stable revenue base within the healthcare sector, particularly in the medical devices industry.
- Positive Operating Cash Flow: Analysis of the cash flow statements indicates consistent net cash provided by operating activities, reflecting the company’s ability to generate cash from core operations, which supports financial stability and operational efficiency.
- Focused Product Segment: Revenue product segment data suggests a strong contribution from key product categories, providing a reliable income stream and positioning Embecta as a specialized player in its niche within the medical devices industry.
Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MarketSnap estimates EMBC intrinsic value between $8.19 – $17.59 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about EMBC valuation
Is Embecta Corp. (EMBC) overvalued or undervalued right now?
MarketSnap estimates intrinsic value for Embecta Corp. (EMBC) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is EMBC a buy, hold, or sell for long-term investors?
MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether EMBC trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is EMBC’s P/E ratio?
You can see EMBC’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for EMBC?
MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is EMBC a good long-term investment?
Whether EMBC fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
EMBC
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
10.12
Trading Metrics:
| Open: | 6.25 | Previous Close: | 6.08 | |
| Day Low: | 6.25 | Day High: | 6.78 | |
| Year Low: | 2.77 | Year High: | 14.91 | |
| Price Avg 50: | 5.78 | Price Avg 200: | 6.37 | |
| Volume: | 551700 | Average Volume: | 1.37M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
